ACAD News Alert Acadia Pharmaceuticals Inc (ACAD) 34.25 01/12/2015
Post# of 64200
Posted On: 01/12/2015 4:49:04 PM
Acadia Pharmaceuticals Inc (ACAD) 34.25 $ACAD
After Yesterday's Rally of 2.68% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jan 09, 4:41PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $31.86 to a high of $33.73. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $32.62 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.25 (+0.88)
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1
at The Street - Thu Jan 08, 12:09PM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
OREX: 5.75 (-0.03), BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), ACAD: 34.25 (+0.88), PCYC: 123.71 (-0.49), GILD: 101.21 (-1.00), NPSP: 45.35 (+3.44), SNY: 44.92 (+0.37), FOLD: 8.88 (+0.04), CELG: 117.00 (+3.33)
Acadia Pharmaceuticals Up 17.9% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Tue Jan 06, 5:24PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 17.86% as of today's recent price of $30.98.
ACAD: 34.25 (+0.88)
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
Business Wire - Tue Jan 06, 8:02AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in San Francisco.
ACAD: 34.25 (+0.88), JPM: 58.83 (-0.51)
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 22.3% (ACAD)
Comtex SmarTrend(R) - Mon Dec 29, 9:21AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 22.28% as of today's recent price of $32.14.
ACAD: 34.25 (+0.88)
Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
at The Street - Wed Dec 24, 8:57AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACAD: 34.25 (+0.88)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 104.58 (-0.36), ACAD: 34.25 (+0.88), GILD: 101.21 (-1.00), CLDX: 19.03 (-0.08)
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Tue Dec 23, 11:40AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACAD: 34.25 (+0.88)
Acadia Pharmaceuticals Shares Up 19.8% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Dec 17, 5:06PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 19.84% as of today's recent price of $31.50.
ACAD: 34.25 (+0.88)
Cramer's Lightning Round - I Don't Want To Touch Fertilizer (12/12/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 14, 5:42AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday December 12. Bullish Calls: TrueCar (NASDAQ: TRUE ): "We like these companies. It is good. It is up on a spike, but I like it." Acadia...
MEMP: 14.93 (-0.52), SWX: 61.66 (-0.11), ACAD: 34.25 (+0.88), AGU: 100.54 (+0.99), TRUE: 20.80 (-0.45), PG: 89.92 (-0.33), TWTR: 39.37 (-0.80)
'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter
at The Street - Sat Dec 13, 5:00AM CST
Cramer likes Acadia Pharmaceuticals and TrueCar but is avoiding Agrium.
MEMP: 14.93 (-0.52), SWX: 61.66 (-0.11), ACAD: 34.25 (+0.88), AGU: 100.54 (+0.99), TRUE: 20.80 (-0.45), PG: 89.92 (-0.33), TWTR: 39.37 (-0.80)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 160.74 (-0.88), SWX: 61.66 (-0.11), HON: 98.45 (-0.48), NKE: 95.86 (-0.13), CHTR: 163.85 (+1.87), BBRY: 10.12 (-0.26), XON: 29.50 (-0.58), RMTI: 11.81 (+0.94), KMX: 64.35 (-0.69), MEMP: 14.93 (-0.52), ACAD: 34.25 (+0.88), PAYX: 47.08 (-0.06), AGU: 100.54 (+0.99), TRUE: 20.80 (-0.45), LOW: 67.85 (-0.48), TWTR: 39.37 (-0.80), REGN: 413.33 (+2.29), JOY: 43.34 (-0.85), FDX: 172.57 (-0.09), LBRDA: 48.99 (+0.10), FINL: 24.82 (+0.40), ORCL: 43.27 (-0.12), DRI: 59.84 (-0.05), BAX: 72.72 (+0.34), RHT: 67.62 (-1.12), AGIO: 131.55 (+3.43), PAY: 36.18 (-1.06), PG: 89.92 (-0.33)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), ACAD: 34.25 (+0.88), NBIX: 29.51 (+1.22), HALO: 14.57 (+0.54)
Acadia Pharmaceuticals Has Returned 25.8% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Dec 10, 11:04AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 25.78% as of today's recent price of $33.06.
ACAD: 34.25 (+0.88)
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders
Business Wire - Mon Dec 08, 8:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID(TM) (pimavanserin) for Parkinson's disease psychosis (PDP) at the 10th Annual International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders held from December 5-7 in Nice, France. Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.
ACAD: 34.25 (+0.88)
Shares of ACAD Up 15.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 9:55AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 15.85% as of today's recent price of $30.45.
ACAD: 34.25 (+0.88)
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 8:01AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACAD: 34.25 (+0.88)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 25, 2:06AM CST
CXO: 95.08 (-4.34), CAM: 44.45 (-1.75), MDLZ: 36.87 (-0.35), MON: 119.56 (+0.52), DAL: 46.06 (-0.82), KSU: 113.30 (-0.95), CFX: 46.98 (-1.03), KORS: 69.33 (+0.07), RL: 174.42 (-1.57), PCP: 225.75 (-3.80), GOOG: 492.55 (-3.62), MOH: 50.13 (-0.73), PBR: 6.57 (-0.49), HLT: 25.45 (-0.26), DLTR: 69.43 (-0.03), LYB: 76.15 (-2.83), COF: 79.06 (-0.31), FOXA: 35.38 (unch), ABBV: 65.76 (-0.02), LOW: 67.85 (-0.48), REGN: 413.33 (+2.29), MA: 83.36 (-1.08), MU: 31.66 (-1.87), FB: 76.72 (-1.02), LNG: 68.48 (-0.79), NFX: 22.73 (-1.77), PXD: 134.93 (-7.59), ALXN: 183.36 (-0.91), ICPT: 146.18 (-3.82), CTSH: 54.15 (+0.03), ADSK: 57.29 (-0.98), DHI: 26.08 (+0.02), CCI: 81.52 (-0.10), ACT: 272.28 (+3.60), LBTYK: 46.17 (+0.17), MDT: 74.47 (+0.07), C: 50.38 (-0.40), ILMN: 190.10 (-4.70), AON: 93.44 (-1.34), ADBE: 71.12 (-0.72), MMC: 56.10 (-0.61), HUM: 145.51 (-1.24), AGN: 219.58 (+4.18), ACAD: 34.25 (+0.88), LBTYA: 47.61 (+0.01), GOOGL: 497.06 (-3.66), AAPL: 109.25 (-2.76), APD: 142.37 (-0.99), HRB: 32.94 (-0.38), GLNG: 31.08 (-0.63), BAC: 16.68 (-0.30), NFLX: 318.83 (-10.46), HCA: 72.20 (-2.45), BIDU: 220.89 (-6.01), DVA: 74.42 (-0.80), KITE: 82.35 (+3.21), MHK: 157.76 (-0.59), CP: 176.96 (-2.03), BABA: 101.62 (-1.40)
Schizophrenia Therapeutics Market 2018 - First-Generation and Second-Generation Antipsychotics Segments Analyzed at ReportsnReports.com
PRWeb - Mon Nov 24, 11:30PM CST
Schizophrenia is a condition in which people interpret reality abnormally. The symptoms of schizophrenia can be managed through medication and psychological therapy. Increase in aging population, increased incidences of schizophrenia and rising awareness about mental illnesses are some of the key factors which are propelling the growth of the global schizophrenia therapeutics market. Awareness about schizophrenia among physicians and patients is also going to be a major factor which will increase the demand of schizophrenia drugs in the market.
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), ACAD: 34.25 (+0.88), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), NVS: 95.48 (-0.64)
Acadia Pharmaceuticals Earnings Review: 14 Days after Announcement Shares Up 0.8% (ACAD)
Comtex SmarTrend(R) - Mon Nov 24, 8:44AM CST
14 days ago, on November 10th, 2014, Acadia Pharmaceuticals (NASDAQ:ACAD) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $72.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.25 per share on sales of $15.0 thousand, missing EPS estimates by $0.03 and matching revenue estimates. Since the company's report, shares of Acadia Pharmaceuticals have risen from $28.21 to $28.43, representing a gain of 0.8% in the past 14 days.
ACAD: 34.25 (+0.88)
After Yesterday's Rally of 2.68% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jan 09, 4:41PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $31.86 to a high of $33.73. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $32.62 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 34.25 (+0.88)
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1
at The Street - Thu Jan 08, 12:09PM CST
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
OREX: 5.75 (-0.03), BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), ACAD: 34.25 (+0.88), PCYC: 123.71 (-0.49), GILD: 101.21 (-1.00), NPSP: 45.35 (+3.44), SNY: 44.92 (+0.37), FOLD: 8.88 (+0.04), CELG: 117.00 (+3.33)
Acadia Pharmaceuticals Up 17.9% Since SmarTrend Uptrend Call (ACAD)
Comtex SmarTrend(R) - Tue Jan 06, 5:24PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 3 months, Acadia Pharmaceuticals has returned 17.86% as of today's recent price of $30.98.
ACAD: 34.25 (+0.88)
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
Business Wire - Tue Jan 06, 8:02AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in San Francisco.
ACAD: 34.25 (+0.88), JPM: 58.83 (-0.51)
Uptrend Call Working As Acadia Pharmaceuticals Stock Rises 22.3% (ACAD)
Comtex SmarTrend(R) - Mon Dec 29, 9:21AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 22.28% as of today's recent price of $32.14.
ACAD: 34.25 (+0.88)
Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
at The Street - Wed Dec 24, 8:57AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate
ACAD: 34.25 (+0.88)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 104.58 (-0.36), ACAD: 34.25 (+0.88), GILD: 101.21 (-1.00), CLDX: 19.03 (-0.08)
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Tue Dec 23, 11:40AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACAD: 34.25 (+0.88)
Acadia Pharmaceuticals Shares Up 19.8% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Dec 17, 5:06PM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 19.84% as of today's recent price of $31.50.
ACAD: 34.25 (+0.88)
Cramer's Lightning Round - I Don't Want To Touch Fertilizer (12/12/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 14, 5:42AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday December 12. Bullish Calls: TrueCar (NASDAQ: TRUE ): "We like these companies. It is good. It is up on a spike, but I like it." Acadia...
MEMP: 14.93 (-0.52), SWX: 61.66 (-0.11), ACAD: 34.25 (+0.88), AGU: 100.54 (+0.99), TRUE: 20.80 (-0.45), PG: 89.92 (-0.33), TWTR: 39.37 (-0.80)
'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter
at The Street - Sat Dec 13, 5:00AM CST
Cramer likes Acadia Pharmaceuticals and TrueCar but is avoiding Agrium.
MEMP: 14.93 (-0.52), SWX: 61.66 (-0.11), ACAD: 34.25 (+0.88), AGU: 100.54 (+0.99), TRUE: 20.80 (-0.45), PG: 89.92 (-0.33), TWTR: 39.37 (-0.80)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 160.74 (-0.88), SWX: 61.66 (-0.11), HON: 98.45 (-0.48), NKE: 95.86 (-0.13), CHTR: 163.85 (+1.87), BBRY: 10.12 (-0.26), XON: 29.50 (-0.58), RMTI: 11.81 (+0.94), KMX: 64.35 (-0.69), MEMP: 14.93 (-0.52), ACAD: 34.25 (+0.88), PAYX: 47.08 (-0.06), AGU: 100.54 (+0.99), TRUE: 20.80 (-0.45), LOW: 67.85 (-0.48), TWTR: 39.37 (-0.80), REGN: 413.33 (+2.29), JOY: 43.34 (-0.85), FDX: 172.57 (-0.09), LBRDA: 48.99 (+0.10), FINL: 24.82 (+0.40), ORCL: 43.27 (-0.12), DRI: 59.84 (-0.05), BAX: 72.72 (+0.34), RHT: 67.62 (-1.12), AGIO: 131.55 (+3.43), PAY: 36.18 (-1.06), PG: 89.92 (-0.33)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), ACAD: 34.25 (+0.88), NBIX: 29.51 (+1.22), HALO: 14.57 (+0.54)
Acadia Pharmaceuticals Has Returned 25.8% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Wed Dec 10, 11:04AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 25.78% as of today's recent price of $33.06.
ACAD: 34.25 (+0.88)
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders
Business Wire - Mon Dec 08, 8:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID(TM) (pimavanserin) for Parkinson's disease psychosis (PDP) at the 10th Annual International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders held from December 5-7 in Nice, France. Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.
ACAD: 34.25 (+0.88)
Shares of ACAD Up 15.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 9:55AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on October 17th, 2014 at $26.29. In approximately 2 months, Acadia Pharmaceuticals has returned 15.85% as of today's recent price of $30.45.
ACAD: 34.25 (+0.88)
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 8:01AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACAD: 34.25 (+0.88)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 25, 2:06AM CST
CXO: 95.08 (-4.34), CAM: 44.45 (-1.75), MDLZ: 36.87 (-0.35), MON: 119.56 (+0.52), DAL: 46.06 (-0.82), KSU: 113.30 (-0.95), CFX: 46.98 (-1.03), KORS: 69.33 (+0.07), RL: 174.42 (-1.57), PCP: 225.75 (-3.80), GOOG: 492.55 (-3.62), MOH: 50.13 (-0.73), PBR: 6.57 (-0.49), HLT: 25.45 (-0.26), DLTR: 69.43 (-0.03), LYB: 76.15 (-2.83), COF: 79.06 (-0.31), FOXA: 35.38 (unch), ABBV: 65.76 (-0.02), LOW: 67.85 (-0.48), REGN: 413.33 (+2.29), MA: 83.36 (-1.08), MU: 31.66 (-1.87), FB: 76.72 (-1.02), LNG: 68.48 (-0.79), NFX: 22.73 (-1.77), PXD: 134.93 (-7.59), ALXN: 183.36 (-0.91), ICPT: 146.18 (-3.82), CTSH: 54.15 (+0.03), ADSK: 57.29 (-0.98), DHI: 26.08 (+0.02), CCI: 81.52 (-0.10), ACT: 272.28 (+3.60), LBTYK: 46.17 (+0.17), MDT: 74.47 (+0.07), C: 50.38 (-0.40), ILMN: 190.10 (-4.70), AON: 93.44 (-1.34), ADBE: 71.12 (-0.72), MMC: 56.10 (-0.61), HUM: 145.51 (-1.24), AGN: 219.58 (+4.18), ACAD: 34.25 (+0.88), LBTYA: 47.61 (+0.01), GOOGL: 497.06 (-3.66), AAPL: 109.25 (-2.76), APD: 142.37 (-0.99), HRB: 32.94 (-0.38), GLNG: 31.08 (-0.63), BAC: 16.68 (-0.30), NFLX: 318.83 (-10.46), HCA: 72.20 (-2.45), BIDU: 220.89 (-6.01), DVA: 74.42 (-0.80), KITE: 82.35 (+3.21), MHK: 157.76 (-0.59), CP: 176.96 (-2.03), BABA: 101.62 (-1.40)
Schizophrenia Therapeutics Market 2018 - First-Generation and Second-Generation Antipsychotics Segments Analyzed at ReportsnReports.com
PRWeb - Mon Nov 24, 11:30PM CST
Schizophrenia is a condition in which people interpret reality abnormally. The symptoms of schizophrenia can be managed through medication and psychological therapy. Increase in aging population, increased incidences of schizophrenia and rising awareness about mental illnesses are some of the key factors which are propelling the growth of the global schizophrenia therapeutics market. Awareness about schizophrenia among physicians and patients is also going to be a major factor which will increase the demand of schizophrenia drugs in the market.
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), ACAD: 34.25 (+0.88), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), NVS: 95.48 (-0.64)
Acadia Pharmaceuticals Earnings Review: 14 Days after Announcement Shares Up 0.8% (ACAD)
Comtex SmarTrend(R) - Mon Nov 24, 8:44AM CST
14 days ago, on November 10th, 2014, Acadia Pharmaceuticals (NASDAQ:ACAD) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $72.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.25 per share on sales of $15.0 thousand, missing EPS estimates by $0.03 and matching revenue estimates. Since the company's report, shares of Acadia Pharmaceuticals have risen from $28.21 to $28.43, representing a gain of 0.8% in the past 14 days.
ACAD: 34.25 (+0.88)
(0)
(0)